All In Biotech

Drug Trial Radar · NCT05874414

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma

Phase 1b/2a Study of GNS561 in Combination With Trametinib in Advanced KRAS Mutated Cholangiocarcinoma

Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

98

Planned (sponsor's estimate)

Start

Aug 21, 2023

Primary completion

Dec 2027

Study completion Jun 2028

Sponsor

Lead sponsor
GenfitIndustry
Sponsor type
Industry
First posted
May 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter Phase 1b/2a study to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of GNS561 in combination with trametinib in Advanced KRAS Mutated Cholangiocarcinoma after failure of standard-of-care first line therapy

Conditions

  • Cholangiocarcinoma

Interventions

  • GNS561 + TrametinibDrug

    GNS561: 50mg, 100mg, 150mg, 200mg and trametinib: 1mg, 1.5mg and 2mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose limiting toxicity (DLT) of GNS561 with trametinib (Phase 1b)Time frame: At the end of Cycle 1 (each Cycle is 21 days)
  2. Objective response rate (ORR) of the combination of GNS561 with trametinib (Phase 2a)Time frame: Up to 11 months (estimated)

Locations

11 sites in 2 countries. Site status is shown where the registry gives one.

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • LACN Aneheim Flagship Office

    Los Angeles, California · Recruiting

  • Orlando Health

    Orlando, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • University Of Chicago Medical Center

    Chicago, Illinois · Recruiting

  • Roswell Park Cancer Institute

    Buffalo, New York · Terminated

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania · Terminated

  • University of Texas, MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • University of Virginia Comprehensive Cancer Center

    Charlottesville, Virginia · Recruiting

  • Froedtert Hospital and the Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

  • Pan American Center for Oncology Trials, LLC

    Rio Piedras, Puerto Rico, Puerto Rico · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.